Optimal threshold of homeostasis model assessment for insulin resistance in an Iranian population: The implication of metabolic syndrome to detect insulin resistance

Diabetes Research and Clinical Practice

Volumn 84, Issue 3, 2009, Pages 279-287

  Esteghamati, Alireza ^a   Ashraf, Haleh ^a   Esteghamati, Abdoul Reza ^b   Meysamie, Alipasha ^c   Khalilzadeh, Omid ^a   Nakhjavani, Manouchehr ^a   Abbasi, Mehrshad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ATPIII; Cut off; HOMA IR; IDF; Insulin resistance; Metabolic syndrome

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; IRAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; FEMALE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; IRAN; LIPIDS; MALE; MEDICAL HISTORY TAKING; METABOLIC SYNDROME X; MIDDLE AGED; MODELS, BIOLOGICAL; ODDS RATIO; PATIENT SELECTION; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 67349197150     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.03.005     Document Type: Article

References (41)

1. Hansen B.C. The metabolic syndrome X. Ann. N. Y. Acad. Sci. 892 (1999) 1-24
2. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: a statement for health care professionals: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
3. Esteghamati A., Abbasi M., Alikhani S., Gouya M.M., Delavari A., Shishehbor M.H., et al. Prevalence, awareness, treatment, and risk factors associated with hypertension in the Iranian population: the national survey of risk factors for noncommunicable diseases of Iran. Am. J. Hypertens. 21 (2008) 620-626
4. Hadaegh F., Bozorgmanesh M.R., Ghasemi A., Harati H., Saadat N., and Azizi F. High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran Lipid and Glucose Study. BMC Public Health 8 (2008) 176
5. Kelishadi R., Derakhshan R., Sabet B., Sarraf-Zadegan N., Kahbazi M., Sadri G.H., et al. The metabolic syndrome in hypertensive and normotensive subjects: the Isfahan Healthy Heart Programme. Ann. Acad. Med. Singapore 34 (2005) 243-249
6. Hadaegh F., Zabetian A., Harati H., and Azizi F. Metabolic syndrome in normal-weight Iranian adults. Ann. Saudi Med. 27 (2007) 18-24
7. DeFronzo R.A., and Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and other atherosclerotic cardiovascular disease. Diabetes Care 14 (1991) 173-194
8. Ascott-Evans B.H. The metabolic syndrome, insulin resistance and cardiovascular disease. SADJ 60 (2005) 122-127
9. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
10. Nakai Y., Fukushima M., Nakaishi S., Kishimoto H., Seino Y., Nagasaka S., et al. The threshold value for insulin resistance on homeostasis model assessment of insulin sensitivity. Diabetic Med. 19 (2002) 344-348
11. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-501
12. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), JAMA 285 (2001) 2486-2497.
13. International Diabetes Federation (IDF): The IDF consensus worldwide definition of the metabolic syndrome [article online]. Available from http://www.idf.org/home.
14. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Targher G., et al. Prevalence of insulin resistance in metabolic disorders. The Bruneck Study. Diabetes 47 (1998) 1643-1649
15. Perkins N.J., and Schisterman E.F. The inconsistency of optimal cut-points using two ROC based criteria. Am. J. Epidemiol. 163 April 1 (7) (2006) 670-675
16. McLaughlin T., Abbasi F., Cheal K., Chu J., Lamendola C., and Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann. Intern. Med. 139 (2003) 802-809
17. Balkau B., and Charles M.A. Comment on the provisional report from the WHO consultation European Group for the Study of Insulin Resistance (EGIR). Diabet. Med. 16 (1999) 442-443
18. Hedblad B., Nilsson P., Janzon L., and Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in nondiabetic subjects. Results from a cross-sectional study in Malmo. Sweden. Diabet. Med. 17 (2000) 299-307
19. Matsumoto K., Miyake S., Yano M., Ueki Y., Yamaguchi Y., Akazawa S., et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 20 (1997) 1562-1568
20. Sumner A.E., and Cowie C.C. Ethnic differences in the ability of triglyceride levels to identify insulin resistance. Atherosclerosis 196 (2008) 696-703
21. Bray G.A., and Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 29 (2006) 109-117
22. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation 106 (1997) 3143-3421.
23. Gharipour M., kelishadi R., Baghaie A.M., Boshtam M., and Rabeie K. Prevalence of metabolic syndrome in an Iranian adult. ARYA J. 1 (1997) 188-189
24. Azizi F., Salehi P., Etemadi A., and Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran lipid and glucose study. Diabetes Res. Clin. Pract. 61 (2003) 29-37
25. Ford E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes care 28 (2005) 2745-2749
26. Lorenzo C., Serrano-Rios M., Martinez-Larrad M.T., Gonzales-Sanchez J.L., Seclen S., Villena A., et al. Geographic variations of the International Diabetes Federation and National Cholesterol Education Program-Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects. Diabetes Care 29 (2006) 685-691
27. Saely C.H., Koch L., Schmid F., Marte T., Aczel S., Langer P., et al. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care 29 (2006) 901-907
28. Marques-Vidal P., Mazoyer E., Bongard V., Gourdy P., Ruidavets J.B., Drouet L., et al. Prevalence of insulin resistance syndrome in Southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 25 (2002) 8
29. Bogardus C., Lillioja S., Mott D.M., Hollenbeck C., and Reaven G. Relationship between degree of obesity and in vivo insulin action in man. Am. J. Physiol. 248 3 Pt 1 (1985) E286-E291
30. Kahn R. The metabolic syndrome (emperor) wears no clothes. Diabetes Care 29 (2006) 1693-1696
31. Shafrir E. Development and consequences of insulin resistance: lessons from animals with hyperinsulinemia. Diabetes Metab. 22 (1996) 122-131
32. Zimmet F., Boyko E.J., Collier G.R., and de Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann. N. Y. Acad. Sci. 892 (1999) 25-44
33. Hanley A.J.G., Wagenknecht L.E., D'Agostino R.B., Zinman B., and Haffner S.M. Identification of subjects with insulin resistance and β-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes 52 (2003) 2740-2747
34. Cheal K.L., Abbasi F., Lamendola C., McLaughlin T., Reaven G.M., and Ford E.S. Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 53 (2004) 1195-1200
35. Sierra-Johnson J., Johnson B.D., Allison T.G., Bailey K.R., Schwartz G.L., and Turner S.T. Correspondence between the Adult Treatment Panel III criteria for metabolic syndrome and insulin resistance. Diabetes Care 29 (2006) 668-672
36. Ascaso ., Romero J.F., Real P., Priego J.T., Valdecabres A., and Carmena C.R. Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population. Med. Clin. (Barc.) 117 (2001) 530-533
37. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
38. Balkau B., and Charles M.A. The European Group for the Study of Insulin Resistance (EGIR) Comment on the provisional report from the WHO consultation. Diabet. Med. 16 (1999) 442-443
39. Yeni-Komshian H., Carantoni M., Abbasi F., and Reaven G.M. Relationship between several surrogate estimates of insulin resistance and qualification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 23 (2000) 171-175
40. Cheal K.L., Abbasi F., Lamendola C., McLaughlin T., Reaven G.M., and Ford E.S. Relationship to Insulin Resistance of the Adult Treatment Panel III Diagnostic Criteria for Identification of the Metabolic Syndrome. Diabetes 53 (2004) 1195-1200
41. A.R. Esteghamati, M. Abbasi, A. Yousefizadeh, The action profile of human insulin: an euglycemic clamp test approach to compare two commercial biosynthetic insulin brands, Iran. J. Diabetes Lipid Disorders 5 (2005) 59-65.